Global Biodefense Market - Segmented by Product and Geography - Growth, Trends, and Forecast (2018 - 2023)
The global biodefense market is expected to register a CAGR of 6.5% during the forecast period, 2018 to 2023. Bioterrorism is the use of biological agents that are harmful for mankind. Biodefense includes medical measures to protect from biological agents. Key factors driving the market growth are rise in technological advancement, such as nanotechnology, database management systems, advanced detector hardware, and gene chips for pathogen detection in the forensic department. Also, the rise in the production of vaccines, enhanced forensics, and quick diagnostic procedures and detection techniques are the factors expected to drive the market growth. Additionally, due to the recent outbreak of Nipah, Ebola, and Zika viruses governments are increasing R&D funding. Increasing investments by regional governments of developed countries for biodefense are also expected to enhance the market growth over the forecast period.
Favorable Government Initiatives
Governments spend huge sums of money every year for the R&D of vaccines in order stay prepared for any bioterrorism attacks. Pharmaceutical companies operating in the biodefense sector have huge opportunities to expand due to governments’ drive to be prepare for any kind of bioterrorism. For instance, in 2004, the US congress passed the Project Bioshield act, calling for USD 5 billion investment for purchasing vaccines which can be used in the event of a bioterrorist attack. This act was designed to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use. Such government initiatives are expected to propel the growth of the biodefense market.
Other factors driving this market are rapid technological advancements and increasing investments by regional governments in developed countries.
Low Market Penetration in Developing and Underdeveloped Countries
The growth of biodefense market may be hampered by the low market penetration in the developing and underdeveloped countries. Limited government interventions and funding for biodefense materials are some of the major reasons restraining the growth of the market. Developed countries have more resources to be prepared for a bio war when compared to developing countries.
North America to Dominate the Market
North America dominated the global biodefense market in 2017, which can be attributed to the increase in government funding to generate and stockpile sufficient vaccines to be used against anthrax through various initiative, such as BioShield act, Biomedical Advanced Research and Development Authority (BARDA), and Joint Program Executive Office for Chemical & Biological Defense. For instance, the US Department of Health and Human Services announced it plans to spend more than USD 25 million on an anthrax antitoxin, as a part of an emergency preparedness plan in 2018. In May 2018, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that USD 25 million was granted to advance the development and manufacture of a vaccine against the Nipah virus (NiV) to major market players, like Profectus BioSciences Inc. and Emergent BioSolutions Inc. The above mentioned initiatives by government are expected to boost the growth of the market in the region.
Key Developments in the Market
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook